Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
7.44
+0.05 (0.68%)
At close: May 6, 2026, 4:00 PM EDT
7.16
-0.28 (-3.76%)
After-hours: May 6, 2026, 6:33 PM EDT
Vanda Pharmaceuticals Revenue
Vanda Pharmaceuticals had revenue of $166.06M in the twelve months ending March 31, 2026, down -17.53% year-over-year. In the year 2025, Vanda Pharmaceuticals had annual revenue of $216.11M with 8.72% growth.
Revenue (ttm)
$166.06M
Revenue Growth
-17.53%
P/S Ratio
2.07
Revenue / Employee
$405,450
Employees
533
Market Cap
447.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 216.11M | 17.33M | 8.72% |
| Dec 31, 2024 | 198.77M | 6.13M | 3.18% |
| Dec 31, 2023 | 192.64M | -61.74M | -24.27% |
| Dec 31, 2022 | 254.38M | -14.30M | -5.32% |
| Dec 31, 2021 | 268.68M | 20.51M | 8.27% |
| Dec 31, 2020 | 248.17M | 20.98M | 9.23% |
| Dec 31, 2019 | 227.19M | 34.07M | 17.64% |
| Dec 31, 2018 | 193.12M | 28.04M | 16.98% |
| Dec 31, 2017 | 165.08M | 19.07M | 13.06% |
| Dec 31, 2016 | 146.02M | 36.09M | 32.83% |
| Dec 31, 2015 | 109.93M | 59.77M | 119.16% |
| Dec 31, 2014 | 50.16M | 16.28M | 48.05% |
| Dec 31, 2013 | 33.88M | 1.15M | 3.52% |
| Dec 31, 2012 | 32.73M | 1.46M | 4.66% |
| Dec 31, 2011 | 31.27M | -4.44M | -12.43% |
| Dec 31, 2010 | 35.71M | 31.16M | 685.16% |
| Dec 31, 2009 | 4.55M | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionVNDA News
- 2 hours ago - Vanda Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 2 hours ago - Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results - PRNewsWire
- 2 days ago - Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years - PRNewsWire
- 7 days ago - Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 - PRNewsWire
- 7 days ago - Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence - PRNewsWire
- 14 days ago - Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors - PRNewsWire
- 27 days ago - Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines - PRNewsWire
- 4 weeks ago - Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists - PRNewsWire